3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
48
Lung Neoplasms
24
Carcinoma, Hepatocellular
24
Small Cell Lung Carcinoma
16
Urinary Bladder Neoplasms
12
Cholangiocarcinoma
12
Breast Neoplasms
10
Biliary Tract Neoplasms
10
Neoplasms
9
Neoplasm Metastasis
9
Liver Neoplasms
9
Pancreatic Neoplasms
7
Carcinoma
6
Endometrial Neoplasms
5
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Neoplasms by Site
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Stomach Neoplasms
3
Respiratory Tract Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Interventions
durvalumab
1
Immunotherapy
1
Bevacizumab
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
durvalumab
×
90 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled